PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
ANNAPOLIS, Md., Aug. 6 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the second quarter of 2009 will be released on Thursday, August 13, 2009.
PharmAthene management will be hosting a conference call to discuss its second quarter 2009 financial results. The call is scheduled to begin at 11:00 a.m. Eastern Time on Thursday, August 13, 2009, and is expected to last approximately 45 minutes.
The dial-in number within the United States is 800-706-7748. The dial-in number for international callers is 617-614-3473. The participant pass code is 28915363.
A replay of the conference call will be available beginning at approximately 2:00 p.m. Eastern Time on August 13, 2009 until approximately 11:59 p.m. Eastern Time on September 11, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant pass code is 35226593.
The conference call will also be web cast and can be accessed from the company's website at www.PharmAthene.com. A link to the web cast may be found under the Investor Relations section of the website. The web cast will be available for 30 days, or until approximately September 12, 2009.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
Third generation rPA anthrax vaccine
Valortim((R)) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Protexia((R)) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
RypVax(TM) -- a recombinant dual antigen vaccine for plague
